Dow Jones futures were roughly flat after hours, while S&P 500 futures and Nasdaq futures rose modestly. Nvidia earnings topped views late, with shares rising, along with AI peers Broadcom, Taiwan ...

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

Scientists have discovered a range of "biomarkers" that could help to improve detection and treatment of gastrointestinal ...

An estimated 5.17% of patients with inflammatory bowel diseases also have bronchiectasis, as shown in chest CT scans of patients with IBD.

Scientists have discovered a range of 'biomarkers' that could help to improve detection and treatment of gastrointestinal ...

PhotoPill Medical, a leader in innovative therapeutic solutions for gastrointestinal diseases, announced today the initiation ...

Enthera Pharmaceuticals ("Enthera"), a clinical-stage biotech company developing a first-in-class antibody therapeutic targeting the Insulin Growth Factor Binding Protein 3 (IGFBP3)/TMEM219 pathway ...

Bengaluru: Experiencing stomach trouble in recent days? It might be more than just a bad meal. Hospitals across the city are ...

There's a need for early anti-tumor necrosis factor (TNF) therapy in inflammatory bowel disease (IBD), with new data showing ...

"Patients presenting with chronic diarrhea, blood in the stool, unexplained nausea and vomiting, or unexplained weight loss ...

Most patients with inflammatory bowel disease (IBD) respond to initial therapy, but an estimated 10% to 40% don't, and some others become resistant to treatment over long periods of time. For many ...